LLY
Eli Lilly and Company [LLY] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
LLY Stock Summary
Top 10 Correlated ETFs
LLY
Top 10 Correlated Stocks
LLY
In the News
US judge overturns Eli Lilly's $176.5 million loss in Teva patent case
Drugmaker Eli Lilly convinced a federal judge in Massachusetts on Tuesday to overturn a $176.5 million jury verdict for Teva Pharmaceutical that found Lilly's migraine drug Emgality infringed three patents related to Teva's rival drug Ajovy.
Don't Miss the Boom: 3 Biotech Stocks Set to Explode Higher
In the dynamic investment realm, one sector that continues to stand out is the area of biotech stocks. Though risky, especially when assessing established firms with market-ready drugs and vast research and development (R&D), the rewards can be significant.
2 Magnificent Dividend Stocks to Buy Right Now
High-quality dividend stocks frequently produce market-beating returns over the long term. Eli Lilly and Novo Nordisk are two blue-chip dividend stocks with rock-solid payouts and strong growth prospects.
FDA Expands Lilly (LLY) Jardiance Label in Chronic Kidney Disease
Following the latest approval, Lilly's (LLY) Jardiance can access a target market that affects more than 35 million adults in the United States.
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
The disruptive effect of weight loss drugs like Ozempic could have surprising impacts on the stock market. Here are potential winners and losers.
The potential ripple effects of GLP-1 weight loss drugs like Ozempic and Wegovy are far-reaching. There could be reduced demand for junk food and increased demand for athletic brands.
3 Magnificent Growth Stocks to Buy Right Now
Some might overlook AstraZeneca, but the stock has strong growth prospects. Eli Lilly continues to fire on all cylinders, with especially big opportunities for Mounjaro.
David vs. Goliath: 3 Stocks Poised to Challenge the ‘Magnificent 7′
The so-called “Magnificent 7” stocks surged in 2023, contributing to a market rebound in an outsized manner. The stocks' presumed overrepresentation has investors considering other investments in their place.
Immunomics Stocks: 3 Ways to Play This Massive AI-Biotech Megatrend
Biotech has long seemed to move slower than its fellow tech fields due to the complexity of biological systems and the difficulty of drug regulations. However, that precedent is set to change thanks to the growing implementation of artificial intelligence ( AI ), upending the field and bringing big changes to the industry.
Are Wall Street Analysts Wrong About Eli Lilly Stock?
After massive gains this year, Eli Lilly's stock has eclipsed many analysts' price targets. Still, the drugmaker has huge growth potential from its current product lineup.
LLY Financial details
LLY Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 20.91 | 23.97 | 27.04 | 31.22 | 31.65 | |
| Net income per share | 3.14 | 4.98 | 6.82 | 6.15 | 6.93 | |
| Operating cash flow per share | 5.38 | 5.19 | 7.16 | 8.01 | 7.86 | |
| Free cash flow per share | 2.44 | 3.74 | 4.93 | 5.94 | 5.1 | |
| Cash per share | 7.21 | 2.62 | 4.06 | 4.31 | 2.45 | |
| Book value per share | 9.56 | 2.8 | 6.22 | 9.9 | 11.81 | |
| Tangible book value per share | 8.25 | -8.16 | -5.94 | -2.68 | -0.56 | |
| Share holders equity per share | 9.56 | 2.8 | 6.22 | 9.9 | 11.81 | |
| Interest debt per share | 10.29 | 17.4 | 18.68 | 18.99 | 18.38 | |
| Market cap | 118.93B | 122.37B | 153.24B | 250.52B | 329.89B | |
| Enterprise value | 121.91B | 135.84B | 166.18B | 263.59B | 344.06B | |
| P/E ratio | 36.8 | 26.38 | 24.74 | 44.88 | 52.83 | |
| Price to sales ratio | 5.53 | 5.48 | 6.24 | 8.85 | 11.56 | |
| POCF ratio | 21.53 | 25.3 | 23.58 | 34.5 | 46.57 | |
| PFCF ratio | 47.45 | 35.13 | 34.28 | 46.5 | 71.71 | |
| P/B Ratio | 12.1 | 46.94 | 27.16 | 27.9 | 30.98 | |
| PTB ratio | 12.1 | 46.94 | 27.16 | 27.9 | 30.98 | |
| EV to sales | 5.67 | 6.09 | 6.77 | 9.31 | 12.05 | |
| Enterprise value over EBITDA | 12.64 | 20.57 | 21.75 | 30.16 | 36.47 | |
| EV to operating cash flow | 22.07 | 28.08 | 25.57 | 36.3 | 48.57 | |
| EV to free cash flow | 48.64 | 39 | 37.17 | 48.93 | 74.79 | |
| Earnings yield | 0.03 | 0.04 | 0.04 | 0.02 | 0.02 | |
| Free cash flow yield | 0.02 | 0.03 | 0.03 | 0.02 | 0.01 | |
| Debt to equity | 1.05 | 6.06 | 2.94 | 1.88 | 1.52 | |
| Debt to assets | 0.23 | 0.4 | 0.36 | 0.35 | 0.33 | |
| Net debt to EBITDA | 0.31 | 2.04 | 1.69 | 1.5 | 1.5 | |
| Current ratio | 1.73 | 1.16 | 1.4 | 1.23 | 1.05 | |
| Interest coverage | 22.74 | 12.42 | 16.85 | 18.71 | 21.49 | |
| Income quality | 1.71 | 0.58 | 1.05 | 1.3 | 1.13 | |
| Dividend Yield | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 | |
| Payout ratio | 0.72 | 0.52 | 0.43 | 0.55 | 0.57 | |
| Sales general and administrative to revenue | 0.28 | 0.28 | 0.25 | 0.23 | 0.23 | |
| Research and developement to revenue | 0.24 | 0.25 | 0.25 | 0.25 | 0.25 | |
| Intangibles to total assets | 0.06 | 0.26 | 0.24 | 0.24 | 0.23 | |
| Capex to operating cash flow | -0.55 | -0.28 | -0.31 | -0.26 | -0.35 | |
| Capex to revenue | -0.14 | -0.06 | -0.08 | -0.07 | -0.09 | |
| Capex to depreciation | -1.88 | -1.1 | -1.53 | -1.21 | -1.63 | |
| Stock based compensation to revenue | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Graham number | 26.01 | 17.71 | 30.89 | 37.03 | 42.9 | |
| ROIC | 0.26 | 0.23 | 0.23 | 0.22 | 0.24 | |
| Return on tangible assets | 0.08 | 0.16 | 0.17 | 0.15 | 0.16 | |
| Graham Net | -19.18 | -30.5 | -32.99 | -30.55 | -30.97 | |
| Working capital | 8.66B | 1.93B | 4.98B | 3.4B | 896.3M | |
| Tangible asset value | 8.47B | -7.6B | -5.39B | -2.43B | -504.2M | |
| Net current asset value | -12.45B | -22.88B | -23.35B | -21.2B | -20.68B | |
| Invested capital | 1.05 | 6.06 | 2.94 | 1.88 | 1.52 | |
| Average receivables | 5.52B | 5.66B | 6.24B | 7.53B | 8.34B | |
| Average payables | 1.31B | 1.31B | 1.51B | 1.64B | 1.8B | |
| Average inventory | 3.78B | 3.14B | 3.59B | 3.93B | 4.1B | |
| Days sales outstanding | 98.1 | 90.62 | 103.06 | 104.75 | 109.45 | |
| Days payables outstanding | 94.11 | 108.64 | 106.95 | 83.38 | 106.29 | |
| Days of inventory on hand | 241.54 | 246.68 | 264.95 | 193.96 | 237.27 | |
| Receivables turnover | 3.72 | 4.03 | 3.54 | 3.48 | 3.33 | |
| Payables turnover | 3.88 | 3.36 | 3.41 | 4.38 | 3.43 | |
| Inventory turnover | 1.51 | 1.48 | 1.38 | 1.88 | 1.54 | |
| ROE | 0.33 | 1.78 | 1.1 | 0.62 | 0.59 | |
| Capex per share | -2.94 | -1.45 | -2.24 | -2.07 | -2.75 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q2
| Metric | History | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 7.21 | 7.71 | 7.68 | 7.71 | 9.24 | |
| Net income per share | 1.06 | 1.61 | 2.04 | 1.49 | 1.96 | |
| Operating cash flow per share | 0.91 | 2.43 | 1.66 | 1.92 | 0.7 | |
| Free cash flow per share | 0.41 | 1.74 | 1.08 | 0.92 | -0.23 | |
| Cash per share | 3.04 | 3.04 | 2.33 | 4.06 | 3.14 | |
| Book value per share | 9.49 | 11.18 | 11.21 | 12.39 | 12.3 | |
| Tangible book value per share | -3.03 | -0.94 | -0.53 | 0.15 | 0.19 | |
| Share holders equity per share | 9.49 | 11.18 | 11.21 | 12.39 | 12.3 | |
| Interest debt per share | 18.77 | 17.73 | 17.18 | 21.02 | 21.05 | |
| Market cap | 291.9B | 291.24B | 347.61B | 310.21B | 421.94B | |
| Enterprise value | 306.1B | 304.51B | 361.79B | 325.54B | 438.07B | |
| P/E ratio | 76.62 | 50.16 | 44.85 | 57.66 | 59.83 | |
| Price to sales ratio | 44.99 | 41.96 | 47.61 | 44.57 | 50.76 | |
| POCF ratio | 355.68 | 133.3 | 220.05 | 179.25 | 667.73 | |
| PFCF ratio | 789.57 | 186.14 | 339.43 | 375.05 | -2.06K | |
| P/B Ratio | 34.16 | 28.92 | 32.64 | 27.72 | 38.14 | |
| PTB ratio | 34.16 | 28.92 | 32.64 | 27.72 | 38.14 | |
| EV to sales | 47.18 | 43.87 | 49.55 | 46.77 | 52.7 | |
| Enterprise value over EBITDA | 147.14 | 126.77 | 151.2 | 191.05 | 188.83 | |
| EV to operating cash flow | 372.97 | 139.38 | 229.02 | 188.11 | 693.25 | |
| EV to free cash flow | 827.96 | 194.63 | 353.27 | 393.6 | -2.14K | |
| Earnings yield | 0 | 0 | 0.01 | 0 | 0 | |
| Free cash flow yield | 0 | 0.01 | 0 | 0 | 0 | |
| Debt to equity | 1.97 | 1.58 | 1.52 | 1.69 | 1.7 | |
| Debt to assets | 0.36 | 0.33 | 0.33 | 0.36 | 0.34 | |
| Net debt to EBITDA | 6.82 | 5.52 | 5.92 | 9 | 6.95 | |
| Current ratio | 1.1 | 1.13 | 1.05 | 1.3 | 1.13 | |
| Interest coverage | 21.32 | 25.02 | 21.86 | 14.53 | 17.67 | |
| Income quality | 0.86 | 1.5 | 0.82 | 1.29 | 0.36 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0.93 | 0.61 | 0.46 | 0.76 | 0.58 | |
| Sales general and administrative to revenue | 0.24 | 0.22 | 0.23 | 0.25 | 0.23 | |
| Research and developement to revenue | 0.27 | 0.26 | 0.27 | 0.29 | 0.28 | |
| Intangibles to total assets | 0.24 | 0.23 | 0.23 | 0.21 | 0.2 | |
| Capex to operating cash flow | -0.55 | -0.28 | -0.35 | -0.52 | -1.32 | |
| Capex to revenue | -0.07 | -0.09 | -0.08 | -0.13 | -0.1 | |
| Capex to depreciation | -1.29 | -1.71 | -1.48 | -2.49 | -2.28 | |
| Stock based compensation to revenue | 0.01 | 0.01 | 0.01 | 0.02 | 0.02 | |
| Graham number | 15.03 | 20.14 | 22.68 | 20.37 | 23.29 | |
| ROIC | 0.06 | 0.07 | 0.06 | 0.04 | 0.06 | |
| Return on tangible assets | 0.03 | 0.04 | 0.05 | 0.03 | 0.04 | |
| Graham Net | -31.06 | -29.3 | -29.39 | -32.28 | -35.08 | |
| Working capital | 1.49B | 1.99B | 896.3M | 4.8B | 2.42B | |
| Tangible asset value | -2.73B | -849.8M | -504.2M | 134.7M | 166.9M | |
| Net current asset value | -21.29B | -19.66B | -20.68B | -21.06B | -22.33B | |
| Invested capital | 1.97 | 1.58 | 1.52 | 1.69 | 1.7 | |
| Average receivables | 7.74B | 8B | 8.44B | 8.79B | 9.1B | |
| Average payables | 1.55B | 1.67B | 1.81B | 1.97B | 2.25B | |
| Average inventory | 3.9B | 3.87B | 4.07B | 4.43B | 4.67B | |
| Days sales outstanding | 106.43 | 107.93 | 105.49 | 116.67 | 99.3 | |
| Days payables outstanding | 104.39 | 95.93 | 112.24 | 111.53 | 123.2 | |
| Days of inventory on hand | 245.33 | 218.35 | 250.55 | 251.45 | 238.95 | |
| Receivables turnover | 0.85 | 0.83 | 0.85 | 0.77 | 0.91 | |
| Payables turnover | 0.86 | 0.94 | 0.8 | 0.81 | 0.73 | |
| Inventory turnover | 0.37 | 0.41 | 0.36 | 0.36 | 0.38 | |
| ROE | 0.11 | 0.14 | 0.18 | 0.12 | 0.16 | |
| Capex per share | -0.5 | -0.69 | -0.58 | -1 | -0.93 |
LLY Frequently Asked Questions
What is Eli Lilly and Company stock symbol ?
Eli Lilly and Company is a US stock , located in Indianapolis of In and trading under the symbol LLY
Is Eli Lilly and Company buy or a sell ?
42 stock analysts have 42 predictions with a medium analyst target price of $366.48. The lowest prediction is $236 and the highest is $630
What is LLY stock prediction ?
With a median analyst target price of $623.5, 2 stock analysts have made 2 forecasts in last 90 days. $617 is the lowest and $630 is the greatest projection.
What is Eli Lilly and Company stock quote today ?
Eli Lilly and Company stock price is $542.2 today.
Is Eli Lilly and Company stock public?
Yes, Eli Lilly and Company is a publicly traded company.
Company Profile
- Volume Average 2.91M
- Market Capitalization 522.62B
- Employee 39K
- CEO Mr. David A. Ricks
- Headquarters Indianapolis,IN,US
- IPO Date 1972-06-01
-
Website
https://www.lilly.com 
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
